SG Americas Securities’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.9M | Buy |
161,026
+40,236
| +33% | +$9.4M | 0.02% | 385 |
|
|
2026
Q1 | $27.6M | Buy |
120,790
+109,577
| +977% | +$24.6M | 0.03% | 430 |
|
|
2025
Q4 | $2.39M | Buy |
11,213
+8,543
| +320% | +$1.76M | ﹤0.01% | 1422 |
|
|
2025
Q3 | $531K | Sell |
2,670
-14,245
| -84% | -$2.66M | ﹤0.01% | 2060 |
|
|
2025
Q2 | $2.92M | Buy |
+16,915
| New | +$2.76M | 0.01% | 632 |
|
|
2025
Q1 | – | Sell |
-33,944
| Closed | -$4.67M | – | 3472 |
|
|
2024
Q4 | $4.67M | Buy |
33,944
+31,723
| +1,428% | +$4.17M | 0.02% | 367 |
|
|
2024
Q3 | $332K | Sell |
2,221
-3,887
| -64% | -$525K | ﹤0.01% | 2051 |
|
|
2024
Q2 | $833K | Buy |
6,108
+4,205
| +221% | +$572K | ﹤0.01% | 1403 |
|
|
2024
Q1 | $288K | Buy |
+1,903
| New | +$272K | ﹤0.01% | 1717 |
|
|
2023
Q2 | – | Sell |
-46,347
| Closed | -$4.97M | – | 2291 |
|
|
2023
Q1 | $4.97M | Buy |
46,347
+25,417
| +121% | +$2.91M | 0.06% | 275 |
|
|
2022
Q4 | $2.56M | Buy |
20,930
+19,838
| +1,817% | +$2.3M | 0.03% | 467 |
|
|
2022
Q3 | $113K | Buy |
+1,092
| New | +$104K | ﹤0.01% | 2767 |
|
|
2022
Q2 | – | Sell |
-942
| Closed | -$111K | – | 3409 |
|
|
2022
Q1 | $111K | Buy |
942
+142
| +18% | +$16.4K | ﹤0.01% | 2725 |
|
|
2021
Q4 | $108K | Sell |
800
-2,454
| -75% | -$365K | ﹤0.01% | 3043 |
|
|
2021
Q3 | $519K | Buy |
3,254
+727
| +29% | +$99.5K | ﹤0.01% | 2464 |
|
|
2021
Q2 | $332K | Buy |
+2,527
| New | +$337K | ﹤0.01% | 2120 |
|
|
2021
Q1 | – | Sell |
-1,971
| Closed | -$329K | – | 3268 |
|
|
2020
Q4 | $329K | Buy |
1,971
+804
| +69% | +$133K | ﹤0.01% | 2302 |
|
|
2020
Q3 | $180K | Buy |
+1,167
| New | +$168K | ﹤0.01% | 2202 |
|
|
2020
Q2 | – | Sell |
-2,213
| Closed | -$249K | – | 3679 |
|
|
2020
Q1 | $249K | Sell |
2,213
-1,758
| -44% | -$228K | ﹤0.01% | 2356 |
|
|
2019
Q4 | $552K | Sell |
3,971
-6,175
| -61% | -$686K | 0.01% | 1687 |
|
|
2019
Q3 | $977K | Sell |
10,146
-2,881
| -22% | -$321K | 0.01% | 1413 |
|
|
2019
Q2 | $1.5M | Buy |
13,027
+10,939
| +524% | +$1.31M | 0.01% | 1188 |
|
|
2019
Q1 | $246K | Buy |
2,088
+234
| +13% | +$20.5K | ﹤0.01% | 2422 |
|
|
2018
Q4 | $116K | Buy |
+1,854
| New | +$116K | ﹤0.01% | 2647 |
|
|
2018
Q3 | – | Sell |
-11,461
| Closed | -$762K | – | 3128 |
|
|
2018
Q2 | $762K | Buy |
+11,461
| New | +$754K | 0.01% | 1689 |
|
Other funds holding ASND
RCM
ACA
JT
SG Americas Securities's ASND Position: Q2 2026 in Review
SG Americas Securities increased its Ascendis Pharma A/S (ASND) stake by 33% in Q2 2026, buying an estimated $9.4M and bringing the position to 161,026 shares worth $42.9M. The position accounts for 0.02% of the portfolio, ranked #385.
SG Americas Securities first reported a position in ASND in Q2 2018 and has held it in 25 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- SG Americas Securities held 161,026 shares of Ascendis Pharma A/S worth $42.9M as of Q2 2026.
- SG Americas Securities bought 40,236 Ascendis Pharma A/S shares in Q2 2026, an estimated $9.4M.
- Ascendis Pharma A/S made up 0.02% of SG Americas Securities's portfolio in Q2 2026, its #385 holding.
- SG Americas Securities first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 25 quarters since.
- 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.